Overview

Description

  • Nature

    Synthetic

Associated products

Specifications

Our Abpromise guarantee covers the use of ab139976 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-MUC16 antibody [EPSISR23] (ab134093)

  • Form

    Liquid
  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

General Info

  • Alternative names

    • CA 125
    • CA-125
    • CA125
    • CA125 ovarian cancer antigen
    • Cancer antigen 125
    • FLJ14303
    • MUC 16
    • MUC-16
    • MUC16
    • MUC16_HUMAN
    • Mucin 16
    • Mucin 16 cell surface associated
    • Mucin-16
    • Mucin16
    • Ovarian cancer related tumor marker CA125
    • Ovarian cancer-related tumor marker CA125
    • Ovarian carcinoma antigen CA125
    see all
  • Function

    Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
  • Tissue specificity

    Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas.
  • Sequence similarities

    Contains 2 ANK repeats.
    Contains 56 SEA domains.
  • Domain

    Composed of three domains, a Ser-, Thr-rich N-terminal domain, a repeated domain containing more than 60 partially conserved tandem repeats of 156 amino acids each (AAs 12061-21862) and a C-terminal transmembrane contain domain with a short cytoplasmic tail.
  • Post-translational
    modifications

    Heavily O-glycosylated; expresses both type 1 and type 2 core glycans.
    Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans.
    May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space.
    May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts.
  • Cellular localization

    Cell membrane. Secreted > extracellular space. May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.
  • Information by UniProt

References

ab139976 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up